Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oshadi Icp in Type 1 Diabetes Mellitus
NCT01772251Phase 2Completed
- Sponsor
- Oshadi Drug Administration Ltd.
- Start
- Feb 2013
- Primary completion
- Jun 2013
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of insulin (oral, Oshadi Icp formulation) in type 1 diabetes mellitus (T1D), sponsored by Oshadi Drug Administration Ltd. Primary endpoint: Adverse events and serious adverse events occurence at Day 23. Started Feb 2013; status: completed.
02
Drugs
insulin (oral, Oshadi Icp formulation)
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT01772251.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01772251.